Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

Effect of 1-L-MT on immunotherapy of diffuse large B-cell lymphoma via downregulation of PD-L1.

View Full Paper
Ask AI
Bookmark
Share

Authors

SCSun ChengtaoXXXue XuCYChunping Yao

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Chengtao et al. (2024) studied this question.

synapsesocial.com/papers/68e67069b6db6435875fb218https://doi.org/10.1200/jco.2024.42.16_suppl.e19066
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade2024 · 18 citations
  2. 2Abstract 3963: Indoleamine 2,3-dioxygenase 1 (IDO1) regulates immune evasion in lymphoma2024
  3. 3Enhancing Immunotherapy in Diffuse Large B-Cell Lymphoma: The Synergistic Potential of Metabolic Checkpoint Inhibitors and Immunomodulation2026 · 1 citations
  4. 4Cutaneous diffuse large B-cell lymphoma induce a macrophage immunosuppressive phenotype through IL-10 secretion2025
  5. 5Comparison of anti-PD-1/PD-L1-based regimens in relapsed/refractory diffuse large B-cell lymphoma: a meta-analysis2025